scientific advisors research partners our manufacturing our science scientific platform car technology tcr technology publications pipeline clinical pre clinical therapeutic areas investor relations stock information news & events media sec filings annual reports corporate governance investor faq working at juno current job openings our viewpoints about us management team board of directors scientific founders scientific advisors research partners our manufacturing our science scientific platform car technology tcr technology publications pipeline clinical pre clinical therapeutic areas investor relations stock information news & events media sec filings annual reports corporate governance investor faq working at juno current job openings our viewpoints breakthrough immunotherapies for cancer re engaging the body s immune system to treat cancer overview juno therapeutics is a clinical stage company developing novel cellular immunotherapies based on two distinct and complementary platforms chimeric antigen receptors cars and t cell receptors tcrs technologies . our goal is to revolutionize medicine by re engaging the body s immune system to treat cancer . juno therapeutics adds adenosine receptor antagonist through acquisition of redoxtherapies the acquisition provides juno with an exclusive license to vipadenant a small molecule adenosine a2a a2a receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers . juno intends to explore this molecule in combination with its engineered t cell platform and may over time explore it in other areas as well . in addition to vipadenant juno has acquired proprietary know how and intellectual property pertaining to the development of a2ar antagonists in combination with immuno modulatory agents such as the company s engineered t cells . our science the use of human t cells as therapeutics to re engage the immune system has the potential to revolutionize the way cancer is treated . juno s technologies genetically engineer a patient s own t cells to recognize and kill cancer cells . these cellular therapies have the potential to be effective regardless of the type of previous treatments patients have experienced and may avoid the long term side effects associated with current treatments . we use two different technologies to target cancer cells and activate t cells cars and tcrs . juno spotlights jun 26 2015 juno named to mit technology review s 50 smartest companies 2015 by administrator home page read more juno s media page media link chimeric antigen receptors cars chimeric antigen receptor car technology directs t cells to recognize cancer cells based on expression of specific cell surface proteins . learn more t cell receptors tcrs high affinity tcr technology provides t cells with a specific t cell receptor that recognizes cancer cells based on expression of specific proteins inside the cell or on the cell surface . learn more for patients t cell immunotherapy using car and tcr technologies have shown promising results in early clinical trials and may offer new options for patients with cancer . learn more contact 307 westlake avenue n. suite 300 seattle wa 98109 206.582.1600 email inquiry juno is hiring browse our current job openings 2016 juno therapeutics . all rights reserved terms & conditions